GlaxoSmithKline plc (LON:GSK) had its price objective hoisted by investment analysts at Jefferies Group from GBX 1,900 ($23.51) to GBX 1,950 ($24.13) in a report issued on Thursday. The firm currently has a “buy” rating on the stock. Jefferies Group’s price target points to a potential upside of 14.71% from the company’s previous close.
Other research analysts also recently issued research reports about the stock. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research report on Monday, June 20th. Deutsche Bank AG reissued a “hold” rating and set a GBX 1,870 ($23.14) target price on shares of GlaxoSmithKline plc in a research note on Wednesday. HSBC reissued a “buy” rating and set a GBX 1,970 ($24.38) target price on shares of GlaxoSmithKline plc in a research note on Monday, September 12th. Berenberg Bank set a GBX 1,885 ($23.33) target price on shares of GlaxoSmithKline plc and gave the stock a “neutral” rating in a research note on Tuesday, August 9th. Finally, Beaufort Securities reissued a “buy” rating on shares of GlaxoSmithKline plc in a research note on Tuesday, June 21st. Three equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of GBX 1,687.13 ($20.88).
Shares of GlaxoSmithKline plc (LON:GSK) opened at 1700.00 on Thursday. The firm has a 50-day moving average of GBX 1,648.78 and a 200 day moving average of GBX 1,560.13. The company’s market cap is GBX 82.64 billion. GlaxoSmithKline plc has a 52 week low of GBX 1,277.25 and a 52 week high of GBX 1,745.56.
The business also recently announced a dividend, which will be paid on Thursday, October 13th. Investors of record on Thursday, August 11th will be given a GBX 19 ($0.24) dividend. This represents a dividend yield of 1.12%. The ex-dividend date of this dividend is Thursday, August 11th.
In related news, insider Witty,Sir Andrew P sold 10,000 shares of the stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of GBX 1,693 ($20.95), for a total value of £169,300 ($209,529.70). Also, insider Slaoui,Moncef bought 28 shares of the company’s stock in a transaction that occurred on Friday, August 12th. The stock was bought at an average cost of GBX 2,208 ($27.33) per share, for a total transaction of £618.24 ($765.15).
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.